BioCentury | Nov 17, 2014
Company News

BHV Pharma, Libbs deal

...BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to develop and commercialize...
...Brazil, to develop and commercialize remogliflozin etabonate. BHV will receive $1.5 million up front and Libbs...
...2 (SGLT2) inhibitor in Type II diabetics, which is slated to start late this year. Libbs...
BioCentury | Oct 6, 2003
Finance

Ebb & Flow

Those reading ID Biomedical's press release justifying its decision to pull its follow-on on Friday might have asked what happened to the bull market for biotech. Since filing the deal on Sept. 25, IDBE said...
Items per page:
1 - 2 of 2
BioCentury | Nov 17, 2014
Company News

BHV Pharma, Libbs deal

...BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to develop and commercialize...
...Brazil, to develop and commercialize remogliflozin etabonate. BHV will receive $1.5 million up front and Libbs...
...2 (SGLT2) inhibitor in Type II diabetics, which is slated to start late this year. Libbs...
BioCentury | Oct 6, 2003
Finance

Ebb & Flow

Those reading ID Biomedical's press release justifying its decision to pull its follow-on on Friday might have asked what happened to the bull market for biotech. Since filing the deal on Sept. 25, IDBE said...
Items per page:
1 - 2 of 2